Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab with chemoradiotherapy in locally advanced rectal cancer
NCT06770270Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in rectal cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Clinical Complete Response Rate at 12 weeks and Pathological Complete Response Rate at 16 weeks. Started Aug 2024; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06770270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770270.